Experience

CEU Universities
• Spain
• Higher Education
• 1 - 100 Employee
• Research Professor

  • Jan 2019 - Present

Universidad CEU Cardenal Herrera
• Profesor investigador

  • Sep 2018 - Present

Biomedical Research Institute INCLIVA
• Researcher Ramon y Cajal

  • Jan 2012 - Present

UCSF
• United States
• Higher Education
• PhD, Associate Research Scientist

  • Jul 2010 - Feb 2011


Valentia Biopharma S.L.

• Spain
• Biotechnology
• 1 - 100 Employee

• Business Development and Licensing Manager

  • 2011 - 2011

  VALENTIA Biopharma SL, founded in 2006 as a spin-off of the University of Valencia, is a biotechnology company, specialized in Research and Development of innovative drugs for genetic human diseases. We use Drosophila melanogaster as a biomedical model for drug discovery following a new strategy based on the assessment of different drug candidates in the totality of a living organism. By genetic modification we have been able to develop transgenic flies models that reproduces some aspects of the genetic human disease myotonic dystrophy type 1 (DM1, OMIM #160900), a complex genetic human disease caused by the expansion of non-coding CTG repeats in the DMPK gene. DM1 is considered an orphan disease due to its estimated worldwide prevalence 1/20,000. Currently there is no evidence of any effective therapy. This has been the first model we developed in our R&D department and now it is being used with our High Throughput Screening (HTS) technology to find new molecules with therapeutic activity. Our HTS platform allows the testing of thousands of compounds per week, with the differential advantage of working with in vivo models. We have the capability of developing transgenic flies modified genetically that will allow to model any human disease with a known gene target and moreover to perform High Throughput screening in the search of new compounds against the modeled human disease. Show less


UCSF comprehensive cancer research center
• PhD, Postdoc

  • 2005 - Jun 2010